Shares of Haleon plc (NYSE:HLN – Get Free Report) have received a consensus rating of “Moderate Buy” from the seven analysts that are currently covering the stock, Marketbeat reports. Three analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $10.95.
A number of research analysts have commented on the company. Morgan Stanley cut Haleon from an “overweight” rating to an “equal weight” rating in a research note on Friday, January 10th. Sanford C. Bernstein cut Haleon from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 8th.
Read Our Latest Analysis on HLN
Haleon Stock Up 1.7 %
Institutional Trading of Haleon
Large investors have recently modified their holdings of the stock. Dimensional Fund Advisors LP grew its holdings in Haleon by 2.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,007,458 shares of the company’s stock worth $8,322,000 after acquiring an additional 24,673 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its holdings in Haleon by 12.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 13,281 shares of the company’s stock worth $110,000 after acquiring an additional 1,450 shares in the last quarter. Sanctuary Advisors LLC acquired a new position in shares of Haleon during the second quarter worth $1,658,000. GAMMA Investing LLC grew its stake in shares of Haleon by 49.7% during the third quarter. GAMMA Investing LLC now owns 15,043 shares of the company’s stock worth $159,000 after purchasing an additional 4,992 shares in the last quarter. Finally, Atomi Financial Group Inc. grew its stake in shares of Haleon by 48.3% during the third quarter. Atomi Financial Group Inc. now owns 22,518 shares of the company’s stock worth $238,000 after purchasing an additional 7,330 shares in the last quarter. Hedge funds and other institutional investors own 6.67% of the company’s stock.
About Haleon
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.
See Also
- Five stocks we like better than Haleon
- How to buy stock: A step-by-step guide for beginners
- META Stock: Insider Selling Ramps Up—What It Means for Investors
- Where to Find Earnings Call Transcripts
- 3 Chip Stocks Still Trading 50% Below Their 52-Week Highs
- How to Short a Stock in 5 Easy Steps
- U.S. Steel: Will Trump-Backed Nippon Investment Drive Upside?
Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.